Relmada Therapeutics (RLMD) Gross Margin (2012 - 2013)
Relmada Therapeutics' (RLMD) quarterly Gross Margin came in at 8.86% in Q4 2013, down 505.0% year-on-year from 2.19% in Q4 2012, and down 81.99% on a QoQ basis from 49.21% in Q2 2013.
Relmada Therapeutics (RLMD) Gross Margin (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Gross Margin data on file, last reported at 8.86% in Q4 2013.
- On a quarterly basis, Gross Margin fell 505.0% year-over-year to 8.86% in Q4 2013; TTM through Nov 2013 was 19.83%, a N/A change from a year earlier, with the FY2013 full-year figure at 21.31%, down 566.0% from the prior year.
- Gross Margin for Q4 2013 stood at 8.86%, down from 49.21% in the prior quarter.
- Over the last five years, Gross Margin for RLMD reached as high as 49.21% in Q2 2013 and fell as low as 8.86% in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | 8.86% |
| May 31, 2013 | 49.21% |
| Feb 28, 2013 | 20.55% |
| Nov 30, 2012 | 13.91% |
| Aug 31, 2012 | 34.13% |
| May 31, 2012 | 27.00% |